anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Traumatic injuries are common diseases in daily life of people and comprise weapon injuries, falling injuries, beating injuries, spraining injuries, puncture injuries, scratching injuries, motion injuries and the like, injuried parts generally have pains, tumidness, bleeding or fractures, dislocation and the like, and the traumatic injuries further comprise certain visceral injuries. The traumatic injuries take soft tissue hemorrhagic injuries as the main. Microcirculation barriers occur on tissues bearing direct trauma or indirect trauma or long-term strain. Seepage or bleeding occurs on the capillary wall, formation of blood sediments of tissues is caused, aseptic inflammation is caused, and tissue tumidness pains are caused. If the blood sediments cannot be promoted to be absorbed, adhesion can be caused. At present, many methods for treating the traumatic injuries exist, and the external use medicament can rapidly and effectively stop bleeding and remove pains and is a permanent store for treating the traumatic injuries in a family.
Patients receive therapeutic conventional surgery (tumor resection). Patients receive treatment as in arm I with the addition of amifostine trihydrate IV over 15 minutes prior to cisplatin on day 1.
The invention relates to a dental kit used for accelerating the recovery of the tissues affected by the insertion of an implant, and, implicitly, the osteointegration thereof, and also for treating diseases in the oral-maxillofacial area, such as periodontosis. According to the invention, the dental kit comprises two external mouth guards (A and B), the first of which has three work-points, and the second one has two work-points, an external mouth guard (F) with multiple work-points, a material (12) consisting of a polymer with high polarity and an apparatus (D) generating an electromagnetic field which generates, inside the mouth guards (A or B or F), a uniform field with an induction ranging between 0.7 . . . 0.9 mT, with a variation ranging between 5 . . . 10%, in the area subjected to the electromagnetic field, on a distance of 1 cm around the same point, and on a volume as high as possible in the areas where the tooth root or the implant is to be positioned, produced by a current of 200 mA, with a frequency ranging between 7 . . . 8 Hz, preferably 7.69 Hz, the field lines being perpendicular on the target-tissue.
This arm involves a 1 year behavioral weight loss program delivered via weekly videoconference meetings led by a professional weight loss counselor. At the end of 1 year, volunteer participants will take over the leadership role of the meetings for the following year. Volunteers will receive a brief training on how to lead videoconference meetings.
PURPOSE: A liquid formulation of long acting interferon-alpha conjugate is provided to ensure excellent storage stability without viral infection. CONSTITUTION: A liquid formulation of long acting interferon-alpha conjugate contains pharmacologically effective amount of long acting interferon alpha conjugate and albumin-free stabilizing agent. The stabilizing agent includes a buffer solution, sugar alcohol, non-ionic surfactant, and isotonic agent. The IgG region includes IgG, IgA, IgD, IgE or IgM-derived Fc region. The sugar alcohol is mannitol or sorbitol. The buffer solution includes citric acid or phosphoric buffer solution.
Accelerated aerobic glycolysis is one of the main metabolic alterations in cancer, associated with malignancy and tumor growth. Although glycolysis is one of the most studied properties of tumor cells, recent studies demonstrate that oxidative phosphorylation (OxPhos) is the main ATP provider for the growth and development of cancer. In this last regard, the levels of mRNA and protein of OxPhos enzymes and transporters (including glutaminolysis, acetate and ketone bodies catabolism, free fatty acid β-oxidation, Krebs Cycle, respiratory chain, phosphorylating system- ATP synthase, ATP/ADP translocator, Pi carrier) are altered in tumors and cancer cells in comparison to healthy tissues and organs, and non-cancer cells. Both energy metabolism pathways are tightly regulated by transcriptional factors, oncogenes, and tumor-suppressor genes, all of which dictate their protein levels depending on the micro-environmental conditions and the type of cancer cell, favoring cancer cell adaptation and growth. In the present review paper, variation in the mRNA and protein levels as well as in the enzyme/ transporter activities of the OxPhos machinery is analyzed. An integral omics approach to mitochondrial energy metabolism pathways may allow for identifying their use as suitable, reliable biomarkers for early detection of cancer development and metastasis, and for envisioned novel, alternative therapies.
Standard care: Bone-anchored hearing aid (BAHI) abutment incision is coated in bacitracin. A healing cap is placed over the abutment and left for a week. The healing cap is removed on postoperative day 7. Patient is instructed to apply bacitracin ointment to the area for 2 weeks.
Early, goal-directed therapy with timely achievement of hemodynamic stability has been shown to clearly improve outcomes in patients with septic shock. Although Surviving Sepsis Campaign guidelines recommend a weight-based approach to initial fluid resuscitation (i.e. 30ml/kg),1 at present, there are no robust data to support whether dosing based on actual body weight or an alternative correction formula (ideal body weight, adjusted body weight) is superior.

FRISSBE is a prospective, randomized, three-arm parallel-group pilot trial of alternative resuscitation strategies for obese patients with septic shock, looking at feasibility and safety of different weight-based approaches. Subject treatment assignment will not be blinded. Data will be collected and analyzed on an intent-to-treat basis. The study will enroll 60 subjects, with 20 subjects per treatment arm. Subjects will be randomized to receive one of three weight-based initial fluid resuscitation strategies - 30cc/kg ideal body weight (IBW), 30cc/kg adjusted body weight (AdjBW), or 30cc/kg actual body weight (ABW).
The invention discloses an anti-LOX-1 humanized single-chain antibody and a preparation method and application thereof, wherein the anti-LOX-1 humanized single-chain antibody comprises a light chain and a heavy chain, and comprises a group of CDRs: HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR 3; the set of CDRs is at least 30% homologous to the following sequences: the amino acid sequence of the HCDR1 is shown as SEQ ID NO. 1; the amino acid sequence of the HCDR2 is shown as SEQ ID NO. 2; the amino acid sequence of the HCDR3 is shown as SEQ ID NO. 3; the amino acid sequence of LCDR1 is shown in SEQ ID NO. 4; the amino acid sequence of LCDR2 is shown in SEQ ID NO. 5; the amino acid sequence of LCDR3 is shown in SEQ ID NO. 6. The invention provides an ideal material for development of an early diagnosis reagent, a targeted drug-loaded material and a therapeutic drug for atherosclerosis.
Radiation therapy is a critical component in managing many malignancies by improving local control and survival. The benefits of radiation may come at the expense of unintended radiation injury to the surrounding normal tissues, with the heart being one of the most affected organs in thoracic radiation treatments. As cancer survivors live longer, radiation-induced cardiotoxicity (RICT) is now increasingly recognized. In this review, we highlight the spectrum and pathophysiology of RICT. We summarize contemporary recommendations for risk stratification, screening, prevention, and management of RICT. We briefly highlight novel applications for radiation to treat some cardiac conditions such as resistant arrhythmias.
BACKGROUND: Migraine is a severe neurological disorder that is recognized as one of the most common debilitating diseases worldwide. Although the exact cause of migraine is not known, research suggests that inflammation, oxidative stress, mitochondrial dysfunction, and insufficient nutrients may contribute to its development. Studies indicate that nutrition-based approaches are safer and more cost-effective strategies for managing migraine symptoms compared to medication. In this regard, the impact of nutrition, as a complementary medicine, is largely attributed to that of certain nutrients on inflammation and mitochondrial function. It is hypothesized that alpha-linolenic acid and L-carnitine, which possess anti-inflammatory and antioxidant properties, may be synergically beneficial for migraine patients. Therefore, this study will be conducted to assess the efficacy of alpha-linolenic acid and L-carnitine co-supplementation in patients with migraine.
METHODS: This is a parallel, randomized, triple-blind, placebo-controlled clinical trial, in which 80 women aged 20 to 50 years with migraine will be assigned to receive either intervention group (n = 40) receiving both 1000 mg/day flaxseed oil and 500 mg/day L-carnitine simultaneously for 12 weeks, or control group (n = 40) receiving both 1000 mg/day paraffin oil and 500 mg/day maltodextrin as the placebos for the same duration. The primary outcomes include changes in clinical symptoms of migraine, including frequency, severity, and duration of attacks, serum levels of C-reactive protein (CRP), total antioxidant capacity (TAC), nitric oxide (NO), malondialdehyde (MDA), and superoxide dismutase (SOD). Secondary outcomes include mental health, sleep quality, and quality of life (QOL).
DISCUSSION: In this study, we aim to investigate the potential benefits of combining alpha-linolenic acid and L-carnitine as a treatment option for migraine sufferers. Migraine, characterized by recurrent severe headaches, affects a significant portion of the population and can significantly impact an individual's quality of life. By studying alternative therapies such as alpha-linolenic acid and L-carnitine, researchers hope to expand the range of treatment options available and potentially provide relief to migraine sufferers.
TRIAL REGISTRATION: Iranian Registry of Clinical Trials ( www.irct.ir ) (ID: IRCT20121216011763N57). Registration date: 29 March 2023.
TRIAL STATUS: The protocol is version 1.0 dated December 30, 2023. Recruitment began on July 10, 2023, and is expected to be completed by January 22, 2024.
INTRODUCTION AND HYPOTHESIS: We evaluated a pilot multi-component reintegration intervention to improve women's physical and psychosocial quality of life after genital fistula surgery.
METHODS: Twelve women undergoing fistula repair at Mulago Specialized Women and Neonatal Hospital (Kampala, Uganda) anticipated in a 2-week multi-component intervention including health education, psychosocial therapy, physiotherapy, and economic investment. We assessed feasibility through recruitment, retention, and adherence, acceptability through intervention satisfaction, and preliminary effectiveness through reintegration, mental health, physical health, and economic status. We collected quantitative data at enrollment, 6 weeks, 3 months, and 6 months. We conducted in-depth interviews with six participants. Quantitative data are presented descriptively, and qualitative data analyzed thematically.
RESULTS: Participants had a median age of 34.5 years (25.5-38.0), 50% were married/partnered, 42% were separated, 50$ had completed less than primary education, and 67% were unemployed. Mean number of sessions received was 12 for health education (range 5-15), 8 for counseling (range 8-9), and 6 for physiotherapy (range 4-8). Feasibility was demonstrated by study acceptance among all those eligible (100%); comfort with study measures, data collection frequency and approach; and procedural fidelity. Acceptability was high; all participants reported being very satisfied with the intervention and each of the components. Participant narratives echoed quantitative findings and contributed nuanced perspectives to understanding approach and content.
CONCLUSIONS: Our results suggest that the intervention and associated research were both feasible and acceptable, and suggested certain modifications to the intervention protocol to reduce participant burden. Further research to determine the effectiveness of the intervention above and beyond surgery alone with regard to the health and well-being of women with fistulas is warranted.
This group will receive an enhanced music experience. They will listen to pre determined music for 30 minutes per day, 5 days a week, for 4 weeks (10 hours total over 4 weeks). This will be delivered in a hybrid model that will combine, in person, remote, and independent sessions, similar to the Attention Training group. Once they complete the music program, they will have the option to complete the Attention Training.
The University of Tennessee Health Science Center (UTHSC) Memphis Hepatitis C Cooperative Research Center was established in 2000 to support clinical and basic research in understanding the basis for chronic disease in hepatitis C (HCV) infection and response to therapy in clinically infected patients. The primary research goal is to understand why African American (AA) patients with chronic hepatitis C are more susceptible to chronic infection and why their response rate to combination therapy is only 50 percent or less of that for non AA patients. The present study will support this ongoing work by continuing to provide clinical samples from patients with chronic hepatitis C who are undergoing treatment. The specific aims for the 2005-2010 Hepatitis C Cooperative Research Center are: to determine how human leukocyte antigen (HLA) class II-dependent immune regulation and T cell specificities affect differences in immune responses to HCV and response to therapy in AA patients compared to non AA patients; to determine if there is a difference in interferon-induced signaling between patients that respond to therapy and those that do not; and to measure and compare the sustained virologic response to standard treatment for hepatitis C between AA and non AA patients. Researchers plan to continue enrollment of patients to the "African American Response to Therapy for Hepatitis C" study (112 African American patients and 20 Caucasian patients) in order to meet the current specific aims. Participants will include adult African American and Caucasian patients with compensated chronic hepatitis C who have not been previously treated with interferon and/or ribavirin. Patients meeting the entry criteria will be enrolled. The total number of patients to be enrolled is 260 over a 10-year period. In the next 5 years 132 subjects (112 African American, 20 Caucasian) will be studied locally. Patients will be recruited primarily from the clinical practices of the hepatologists at UTHSC. Patients will also be selected from referrals at local Gastroenterology Hepatology clinics and the Memphis Department of Veterans Affairs (VA) Hospital. Patients will be treated with weight based pegylated interferon alfa-2b once weekly and weight based ribavirin twice a day. Duration of treatment with both pegylated interferon alfa-2b and ribavirin will be for up to 72 weeks. Treatment will be discontinued at 24 weeks if there is persistent viremia and the patient wishes to discontinue therapy. Ribavirin will be administered orally at a dose of 13 +/- 2 mg/kg per day twice daily, with 200 mg capsules. Pegylated interferon alpha-2b will be administered by the subcutaneous route.
All patients who scheduled for an elective heart surgery in Royal Infirmary of Edinburgh using a heart-lung machine and the administration of ether-like anaesthetic, isoflurane will be recruited in this study. This is a pilot study to determine the concentration of isoflurane in heart muscle. Isaac and Michael (2005), Hill (1998), Julious (2005) have conducted survey/research to conclude that 30 sample sizes are adequate for a pilot study. Thus, investigators aim to recruit at least 30 sample sizes to allow data (standard deviation, mean etc.) used in sample size estimation for future studies.

The medical and surgical care plans for participants remain as usual in this study. In a normal practise, surgeons will insert a catheter into the blood vessels coming from the heart to deliver solution to stop the contraction of heart for heart procedure. At this moment, two blood samples of about two-teaspoonful in volume will be collected from the in-placed catheters in vein and aorta. Then, the blood samples will be sent to lab to measure the concentration of isoflurane in vein and aorta. Also, the reading of exhausted isoflurane gas on heart-lung machine are routinely monitored and recorded.
This study will recruit male and female adolescents (aged 13-19y). Eligible participants will be booked for an initial visit where parental consent (where necessary ie. under 18 years of age) will be obtained; individuals will then be screened for overall health status. Self-report questionnaires will be administered to participants and will include information on stage of physical development (Tanner Staging), medical history, ethnicity, caffeine use (including CCEDs), gaming, physical activity and smoking status (iPad based). In the second, third and fourth visits, subjects will arrive following a 24-48h abstention from caffeine, alcohol and vigorous exercise and an overnight fast (8h). Participants will undergo three modified oral glucose tolerance tests (OGTT), following administration of either a water placebo (control), a caffeine-free CCED (control) or a caffeine containing CCED (5mg/kg caffeine) in a randomly assigned, double-blind, crossover design. Briefly, subjects will arrive and a baseline blood sample will be obtained (numbing cream will be offered). This will be immediately followed by administration of the treatment. Following a 30min absorption period, a standard OGTT (75g Trutol) will be administered. Additional blood samples will be obtained at 0, 30, 45, 60, 90, and 120min and assessed for glucose, insulin, fatty acids and C-peptide employing standard chemistry procedures. A peripheral IV will be used to obtain the 7 samples reducing needle pokes to one, ideally. Trials will be separated by at least 1wk, but not more than 4wk. Blood samples collected during the OGTT (all time points) will be assessed for metabolic and satiety signally hormone responses (ie. insulin). All subjects will also be asked to provide a saliva sample for genetic analysis. Genetic analysis will be performed by the company 23 \& Me. Subjects will also be asked to provide a midstream urine sample 30 minutes prior to the completion of the OGTT (90min time point +/10 mins). This is to allow for the analysis of caffeine and caffeine metabolites present in the urine, which will give insight into how caffeine is metabolized and excreted differently among individuals.
PURPOSE: To prepare an analgesic agent, containing specific pyrimidine derivatives, having high analgesic actions and hardly causing adverse effects. CONSTITUTION: This analgesic agent contains a compound represented by the formula [=A-B= is =CH-CH= or =N-CR<2> = (R<2> is H, an alkyl, an alkoxy, etc.); Alk is a 2-4C alkylene; R<1> is H, a dialkylaminoalkyl, a carboxyalkyl, an alkoxycarbonylalkyl, etc.; Y is CH or N; Z is a bond or CO; Ar is phenyl, etc.] and/or its salt. The analgesic agent is prepared by combining at least one of the compound represented by the formula and/or its salt with at least one of a solid, a liquid and/or a semiliquid vehicles or an auxiliary, as necessary, one or more other active compounds and converting the resultant mixture into a suitable dosage form.
Alkali metal or amine salts of acrylic acid ester polymers containing carboxyl groups or of copolymers containing carboxyl groups of acrylic acid esters with other ethylenically unsaturated compounds, which salts are soluble in water and, at least in admixture with another organic solvent, advantageously a water-soluble aliphatic alcohol having 1-4 carbon atoms, in polyhalogenated hydrocarbons which are gaseous at room temperature, e.g. trichloro-monofluoromethane, dichloro-difluoromethane or dichloro-tetrafluorethane, are made by polymerizing an acrylic acid ester of an aliphatic alcohol having 1-4 carbon atoms alone or together with another ethylenically unsaturated compound in a water-soluble aliphatic alcohol having 1-4 carbon atoms, subsequently hydrolysing in the resulting polymer a sufficient proportion of the ester groups with an alcohol solution of an alkali metal hydroxide to render the alkali metal salt of the polymer soluble in water, and, if desired, converting the alkali metal salt into an amine salt. Acrylic esters specified are the methyl, ethyl, propyl, isopropyl, isobutyl, sec.-butyl and tert.-butyl esters which may be copolymerized with acrylonitrile, methacrylic esters of alcohols having 1-4 carbon atoms, hexyl acrylate, acrylamide, styrene and vinyl alkyl ketones. Polymerization may be carried out in the presence of a catalyst such as benzoyl, acetyl and acetyl-benzoyl peroxides or cumene and tert.-butyl hydroperoxides, and is preferably effected at reflux temperature with gradual addition of monomer to the reaction mixture. The ester polymers are hydrolysed with alcoholic sodium, potassium or lithium hydroxide; the amine salts may be prepared by acidifying the solution of alkali metal salt of the polymer, separating the acid polymer and then neutralizing it with an amine, e.g. triethanolamine. Specifications 470,867, [Group IV], and 796,319 are referred to.
There is an escalating trend in both the incidence and prevalence of atrial fibrillation (AF). AF is linked to numerous other comorbidities, contributing to the emergence of multimorbidity. The sustained rise in multimorbidity and AF prevalences exerts a significant strain on healthcare systems globally. The understanding of the relation between multimorbidity and AF is essential to determine effective healthcare strategies, improve patient outcomes to adequately address the burden of AF. It not only begins with the accurate identification of comorbidities in the setting of AF. There is also the need to understand the pathophysiology of the different comorbidities and their common interactions, and how multimorbidity influences AF perpetuation. To manage the challenges that rise from the increasing incidence and prevalence of both multimorbidity and AF, such as adverse events and hospitalisations, the treatment of comorbidities in AF has already gained importance and will need to be a primary focus in the forthcoming years. There are numerous challenges to overcome in the treatment of multimorbidity in AF, whereby the identification of comorbidities is essential. Integrated care strategies focused on a comprehensive multimorbidity management with an individual-centred approach need to be determined to improve healthcare strategies and reduce the AF-related risk of frailty, cardiovascular diseases and improve patient outcomes.